NCT06151964 - A Trial to Learn How Safe AZD9550 is in People With or Without Type 2 Diabetes Who Are Overweight or Obese | Biotech Hunter

Enrollment

116

Participants

Timeline

Start Date

September 29, 2023

Primary Completion Date

July 24, 2026

Study Completion Date

July 24, 2026

Conditions

Non-alcoholic Steatohepatitis (NASH)

Interventions

DRUG

AZD9550

Part A: A constant dose Part B: Doses of AZD9550 that increase each week Part C: Doses of AZD9550 that increase every 2 weeks, then every 4 weeks Part D: Doses of AZD9550 that increase every 2 weeks, then every 4 weeks

DRUG

Placebo

Matching administration volumes for SC injection

Trial Locations (15)

1090

COMPLETED

Research Site, Vienna

8036

COMPLETED

Research Site, Graz

39120

RECRUITING

Research Site, Magdeburg

41460

RECRUITING

Research Site, Neuss

89231

RECRUITING

Research Site, Neu-Ulm

V3T 2V6

RECRUITING

Research Site, Surrey

N7T 4X3

NOT_YET_RECRUITING

Research Site, Sarnia

L4A 1H2

NOT_YET_RECRUITING

Research Site, Stouffville

M4G 3E8

RECRUITING

Research Site, Toronto

M4J 5B9

NOT_YET_RECRUITING

Research Site, Toronto

J1L 0H8

NOT_YET_RECRUITING

Research Site, Sherbrooke

812-0025

COMPLETED

Research Site, Fukuoka

160-0004

COMPLETED

Research Site, Shinjuku-ku

565-0853

COMPLETED

Research Site, Suita-shi

752 37

COMPLETED

Research Site, Uppsala